EGFR and neoplasm: Subsequently, doses of 75-150 mg/kg have been shown to result in tumour growth inhibition in a range of human tumour xenograft models including tumours that are PIK3CA mutant, PTEN null, EGFR mutant or wild type, with an associated decrease in AKT and S6 phosphorylation [2], [3], [4], [5], [6].